Error loading player: No playable sources found

AM23-MN-29-O

AM23-MN-29-O: Eyedrops of Human Origin (EDHO)- Guidelines for Production, Clinical Use and Regulation (Enduring)

Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)
$3000
Standard Price
Members save $5

Eyedrops of Human Origin (EDHO) are a form of MPHO (Medical Product of Human Origin) and, as such, should be subject to the same scrutiny and rigidity as other biotherapies which includes blood transfusion and cellular therapies.The ISBT Cellular Therapies Working Party has identified that this area of biotherapy has yet to receive much focus as it straddles the area between ophthalmology units which prescribe them for use and the establishments involved in production, which often include blood banks.A successful workshop was convened in May 2022, which provided a forum for scientists, regulatory authorities, ophthalmologists, and transfusion experts to discuss the production, quality, clinical use, and regulation of these eyedrops of human origin (EDHO). The purpose was to produce expert guidelines and recommendations on these critical issues to ensure quality standardization. The session will focus on the output of this workshop. The two speakers will introduce the biology and properties of eyedrops of human origin. The talks will discuss donor eligibility for both autologous and allogeneic production, the quality control needed to achieve standardization, and a review of the existing data and clinical trials for the efficacy and safety of EDHO. This session will be useful for ophthalmologists to understand the complexities of manufacturing a biotherapy. It will be useful for blood establishments involved in production to understand the quality and regulatory issues and the clinical use of these products. The talk will also review the commercially available preparations.

Learning Objectives

  • To review guidelines for production and manufacture of EDHO
  • To discuss the various clinical conditions for its usage
  • To clarify the complex regulatory and quality issues associated with EDHO

Speaker

Speaker Image for Christian Gabriel
Lecturer, Medical University of Graz

Moderator & Speaker

Speaker Image for DENESE MARKS
Research Program Leader, Australian Red Cross Lifeblood

Tracks

Related Products

Thumbnail for AM24-MN-43-O: Trans, Non-binary, and Gender-Diverse Peoples: How You Can Make a Difference for Donors, Patients, and Communities (Enduring)
AM24-MN-43-O: Trans, Non-binary, and Gender-Diverse Peoples: How You Can Make a Difference for Donors, Patients, and Communities (Enduring)
Many blood operators around the world are implementing individualized donor assessments that welcome more trans, non-binary, and gender-diverse people to donate…
Thumbnail for AM23-ST-04-O: THOR/AABB: Prehospital Transfusion: The Latest Evidence and Expert Discussion (Enduring)
AM23-ST-04-O: THOR/AABB: Prehospital Transfusion: The Latest Evidence and Expert Discussion (Enduring)
Prehospital transfusion is becoming a common event in the USA and around the world…
Thumbnail for AM24-SN-14-O: Blood Donation, Race and Transfusion Medicine: Looking Back to Move Forward (Enduring)
AM24-SN-14-O: Blood Donation, Race and Transfusion Medicine: Looking Back to Move Forward (Enduring)
Race is a sociopolitical and not biological construct. As such, the use of race-based algorithms and disease associations has caused demonstrable harm such as delayed kidney transplant referral and missed diagnoses. The field of transfusion medicine is not immune…
Thumbnail for AM24-ST-22-O: Cryopreserved Platelets: From Bench to Bedside (Enduring)
AM24-ST-22-O: Cryopreserved Platelets: From Bench to Bedside (Enduring)
This session will explore the characteristics of cryopreserved platelets from laboratory studies, followed by the first presentation of the results from the CLIP-II clinical trial…